Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GANX 
Gain Therapeutics Inc (GANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: GANX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.71
1 Year Target Price $7.71
| 3 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.03% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.67M USD | Price to earnings Ratio - | 1Y Target Price 7.71 |
Price to earnings Ratio - | 1Y Target Price 7.71 | ||
Volume (30-day avg) 7 | Beta 0.14 | 52 Weeks Range 1.36 - 3.19 | Updated Date 09/14/2025 |
52 Weeks Range 1.36 - 3.19 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -74.33% | Return on Equity (TTM) -240.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 53661187 | Price to Sales(TTM) 255.5 |
Enterprise Value 53661187 | Price to Sales(TTM) 255.5 | ||
Enterprise Value to Revenue 138.33 | Enterprise Value to EBITDA -1.55 | Shares Outstanding 35948600 | Shares Floating 34610239 |
Shares Outstanding 35948600 | Shares Floating 34610239 | ||
Percent Insiders 3.64 | Percent Institutions 10.56 |
Upturn AI SWOT
Gain Therapeutics Inc
Company Overview
History and Background
Gain Therapeutics Inc. was founded in 2017. It focuses on developing novel allosteric regulators to treat genetically defined neurodegenerative diseases and cancer. The company's platform aims to identify and develop treatments that restore protein function in diseases caused by protein misfolding.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing small molecule therapeutics for diseases with significant unmet medical needs, particularly those involving protein misfolding and aggregation.
- Allosteric Modulator Platform (SEE-Tx): This is Gain's proprietary platform for identifying novel allosteric modulators, which are compounds that bind to a protein and alter its function, rather than directly blocking its active site.
Leadership and Structure
Khaled Attar is the Chief Executive Officer. The company has a board of directors overseeing its strategy and operations. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- GT-02287 (GBA1 program): A small molecule allosteric modulator targeting GBA1 for the treatment of neuronopathic Gaucher disease and Parkinson's disease. Currently in clinical development (Phase 1). No market share yet as it is still in development. Competitors: Sanofi (Genzyme), Takeda, Idorsia, Denali Therapeutics.
- GT-02329 (Asparagine Endopeptidase (AEP) program): An allosteric modulator targeting Asparagine Endopeptidase (AEP) for the treatment of cancer. Currently in preclinical stage. No market share yet as it is still in development. Competitors: Potential large pharma companies developing therapies for solid tumors.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investments in research and development. Focus areas include neurodegenerative diseases and cancer, driven by unmet medical needs and aging populations.
Positioning
Gain Therapeutics is positioned as a biotechnology company specializing in allosteric modulation for treating genetic diseases. Its competitive advantage lies in its SEE-Tx platform and focus on novel drug targets.
Total Addressable Market (TAM)
The TAM for neurodegenerative diseases and cancer is substantial, estimated in the hundreds of billions of dollars. Gain Therapeutics is targeting specific genetic subsets within these larger markets.
Upturn SWOT Analysis
Strengths
- Proprietary SEE-Tx platform for allosteric modulator discovery
- Focus on genetically defined diseases with high unmet need
- Experienced management team
- Early-stage clinical and preclinical pipeline
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Dependence on successful clinical trial outcomes
- Limited number of programs in development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline through new target identification
- Positive clinical trial results leading to regulatory approval
- Securing additional funding through grants or equity offerings
Threats
- Clinical trial failures
- Competition from other companies developing similar therapies
- Regulatory hurdles and delays
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- SNY
- TAK
- IDRS
- DNLI
Competitive Landscape
Gain Therapeutics is an emerging player with a novel technology platform, competing with larger, established pharmaceutical companies. Its advantage lies in its allosteric modulator approach, but it faces challenges in securing funding and navigating the regulatory process.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on advancing its pipeline and securing funding.
Future Projections: Future growth depends on successful clinical trials and potential partnerships. Analyst estimates are based on the potential of their drug candidates.
Recent Initiatives: Recent initiatives include advancing GT-02287 into clinical trials and expanding its research programs.
Summary
Gain Therapeutics is a biotechnology company focusing on novel treatments for neurodegenerative diseases and cancer using its allosteric modulator platform. While the company has promising technology and a focused strategy, it is early stage and faces the typical risks associated with drug development, including clinical trial failures and funding challenges. The success of its clinical programs, especially GT-02287, will be critical for its future. Partnerships and continued funding will be essential for the company to achieve its goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Gain Therapeutics Inc. website
- SEC filings
- Company presentations
- Analyst reports (where available)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gain Therapeutics Inc
Exchange NASDAQ | Headquaters Bethesda, MD, United States | ||
IPO Launch date 2021-03-18 | President, CEO & Director Mr. Gene Mack M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://gaintherapeutics.com |
Full time employees 23 | Website https://gaintherapeutics.com | ||
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.